MAGENTA THERAPEUTICS INC (MGTA) Stock Price, Quote, News and Overview
NASDAQ:MGTA - Nasdaq - US55910K1088 - Common Stock - Currency: USD
MGTA Quote, Performance and Key Statistics
NASDAQ:MGTA (9/11/2023, 8:06:21 PM)
0.6996
-0.06 (-7.74%)
The current stock price of MGTA is 0.6996 USD. In the past month the price decreased by -13.09%. In the past year, price decreased by -58.36%.
MGTA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MGTA
Company Profile
Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Company Info
MAGENTA THERAPEUTICS INC
100 Technology Sq Fl 5
Cambridge MASSACHUSETTS 02139 US
CEO: Jason Gardner
Employees: 67
Company Website: https://www.magentatx.com/
Phone: 18572012700.0
MAGENTA THERAPEUTICS INC / MGTA FAQ
What is the stock price of MAGENTA THERAPEUTICS INC today?
The current stock price of MGTA is 0.6996 USD. The price decreased by -7.74% in the last trading session.
What is the ticker symbol for MAGENTA THERAPEUTICS INC stock?
The exchange symbol of MAGENTA THERAPEUTICS INC is MGTA and it is listed on the Nasdaq exchange.
On which exchange is MGTA stock listed?
MGTA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MAGENTA THERAPEUTICS INC stock?
6 analysts have analysed MGTA and the average price target is 1.02 USD. This implies a price increase of 45.8% is expected in the next year compared to the current price of 0.6996. Check the MAGENTA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MAGENTA THERAPEUTICS INC worth?
MAGENTA THERAPEUTICS INC (MGTA) has a market capitalization of 2.65M USD. This makes MGTA a Nano Cap stock.
How many employees does MAGENTA THERAPEUTICS INC have?
MAGENTA THERAPEUTICS INC (MGTA) currently has 67 employees.
What are the support and resistance levels for MAGENTA THERAPEUTICS INC (MGTA) stock?
MAGENTA THERAPEUTICS INC (MGTA) has a support level at 0.63 and a resistance level at 0.75. Check the full technical report for a detailed analysis of MGTA support and resistance levels.
Should I buy MAGENTA THERAPEUTICS INC (MGTA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MGTA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MGTA, evaluating the profitability, health, valuation and growth aspects
- MAGENTA THERAPEUTICS INC (MGTA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MAGENTA THERAPEUTICS INC (MGTA) Sales and EPS estimates to see what analysts future expectations are.
- MAGENTA THERAPEUTICS INC (MGTA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MAGENTA THERAPEUTICS INC (MGTA) Insider and Institutional Ownership to learn about the owners and their transactions.
- MAGENTA THERAPEUTICS INC (MGTA) Stock Chart to make your own analysis
- MAGENTA THERAPEUTICS INC (MGTA) Latest news and press-releases to stay up to date.
Does MAGENTA THERAPEUTICS INC (MGTA) stock pay dividends?
MGTA does not pay a dividend.
When does MAGENTA THERAPEUTICS INC (MGTA) report earnings?
MAGENTA THERAPEUTICS INC (MGTA) will report earnings on 2023-11-01.
What is the Price/Earnings (PE) ratio of MAGENTA THERAPEUTICS INC (MGTA)?
MAGENTA THERAPEUTICS INC (MGTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
MGTA Technical Analysis
MGTA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGTA. MGTA has a great financial health rating, but its profitability evaluates not so good.
MGTA Financial Highlights
Over the last trailing twelve months MGTA reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 12.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
MGTA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to MGTA. The Buy consensus is the average rating of analysts ratings from 6 analysts.